Retour

Nuwellis, Inc. Announces First Quarter 2024 Financial Results

Stocks Earnings Releases and Operating Results

MINNEAPOLIS, May 07, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the first quarter ended March 31, 2024.

GlobeNewswire Inc. • 07/05/2024 à 14:00:00
Nuwellis, Inc. Common Stock
Address: 12988 VALLEY VIEW ROAD
Postal Code: 55344
City: EDEN PRAIRIE
State: MN
Phone Number: 952-345-4200
Website: https://www.nuwellis.com
Status: Active
Company Info

Nuwellis Inc is a medical device company. Its solutions includes Aquadex Smartflow System and RenalSense Clarity RMS. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Clarity RMS is a kidney monitoring system that continuously measures urine output and flows, automatically displaying real-time data to the medical staff.

List Date2012-02-16
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001506492
Composite figiBBG000QVFRH8
Share Class figiBBG001SNT6T0
Market Cap4,675,223 USD
SIC Code3845
SIC DescriptionELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Total Employees59
Share Class Shares Outstanding18050000
Weighted Shares Outstanding18051055
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
0.256
0.297
0.227
0.231
0.244
Variance
-13.8%
30.84%
-1.3%
-5.33%
-2.01%
Open
0.297
0.227
0.23
0.244
0.249
Highest
0.32
0.301
0.232
0.245
0.258
Lowest
0.32
0.3
0.232
0.245
0.258
History
PeriodVarhighestlowest
1 week
2.81%
0.258
0.232
1 month
-6.23%
0.527
0.156
3 month
-54.93%
0.777
0.156
6 month
-57.33%
0.6099
0.156
1 year
-91.85%
3.14
0.156
3 year
-99.93%
368
0.156
5 year
-99.95%
528.58
0.156
10 year
-99.95%
528.58
0.156
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-08 2023-11-07 2024-03-11
Assets 18,479,000 15,553,000 11,432,000 9,770,000
Current Assets 16,610,000 13,748,000 9,638,000 8,209,000
Current Liabilities 4,107,000 3,825,000 2,992,000 3,172,000
Equity 13,664,000 11,074,000 7,839,000 2,990,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 13,664,000 11,074,000 7,839,000 2,990,000
Liabilities 4,815,000 4,479,000 3,593,000 6,559,000
Liabilities And Equity 18,479,000 15,553,000 11,432,000 9,770,000
Noncurrent Assets 1,869,000 1,805,000 1,794,000 1,561,000
Noncurrent Liabilities 708,000 654,000 601,000 3,387,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-08 2023-11-07 2024-03-11
Exchange Gains/Losses -7,000 1,000 0 -13,000
Net Cash Flow -6,222,000 -2,619,000 -3,966,000 -13,937,000
Net Cash Flow, Continuing -6,215,000 -2,620,000 -3,966,000 -13,924,000
Net Cash Flow From Financing Activities -11,000 2,119,000 -20,000 3,683,000
Net Cash Flow From Financing Activities, Continuing -11,000 2,119,000 -20,000 3,683,000
Net Cash Flow From Investing Activities -98,000 513,000 -121,000 330,000
Net Cash Flow From Investing Activities, Continuing -98,000 513,000 -121,000 330,000
Net Cash Flow From Operating Activities -6,106,000 -5,252,000 -3,825,000 -17,937,000
Net Cash Flow From Operating Activities, Continuing -6,106,000 -5,252,000 -3,825,000 -17,937,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-08 2023-11-07 2024-03-11
Comprehensive Income/Loss -6,486,000 -4,844,000 -3,370,000 -20,278,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -6,486,000 -4,844,000 -3,370,000 -20,278,000
Other Comprehensive Income/Loss -6,486,000 -4,844,000 -3,370,000 -20,278,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-08 2023-11-07 2024-03-11
Basic Earnings Per Share -6 -4 -2 -12
Benefits Costs and Expenses 8,309,000 6,918,000 5,780,000 29,065,000
Cost Of Revenue 759,000 928,000 1,031,000 3,881,000
Costs And Expenses 8,309,000 6,918,000 5,780,000 29,065,000
Diluted Earnings Per Share -6 -4 -2 -12
Gross Profit 1,067,000 1,147,000 1,381,000 4,983,000
Income/Loss From Continuing Operations After Tax -6,485,000 -4,845,000 -3,370,000 -20,209,000
Income/Loss From Continuing Operations Before Tax -6,483,000 -4,843,000 -3,368,000 -20,201,000
Income Tax Expense/Benefit 2,000 2,000 2,000 8,000
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -6,485,000 -4,845,000 -3,370,000 -20,209,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -6,485,000 -4,845,000 -3,370,000 -20,209,000
Net Income/Loss Available To Common Stockholders, Basic -6,485,000 -4,845,000 -3,370,000 -22,627,000
Operating Expenses 6,918,000 6,169,000 4,545,000 22,613,000
Operating Income/Loss -5,851,000 -5,022,000 -3,164,000 -17,630,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 2,300,000
Preferred Stock Dividends And Other Adjustments 0 0 0 2,300,000
Revenues 1,826,000 2,075,000 2,412,000 8,864,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-12 2022-08-11 2022-11-08 2023-03-03
Assets 26,107,000 21,998,000 18,437,000 24,673,000
Current Assets 23,895,000 19,920,000 16,440,000 22,769,000
Current Liabilities 3,392,000 3,459,000 3,611,000 4,688,000
Equity 21,713,000 17,664,000 14,016,000 12,357,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 21,713,000 17,664,000 14,016,000 12,357,000
Liabilities 4,394,000 4,334,000 4,421,000 12,316,000
Liabilities And Equity 26,107,000 21,998,000 18,437,000 24,673,000
Noncurrent Assets 2,212,000 2,078,000 1,997,000 1,904,000
Noncurrent Liabilities 0 0 810,000 7,628,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-12 2022-08-11 2022-11-08 2023-03-03
Exchange Gains/Losses -2,000 1,000 2,000 -7,000
Net Cash Flow -4,905,000 -3,955,000 -3,292,000 8,995,000
Net Cash Flow, Continuing -4,903,000 -3,956,000 -3,294,000 9,002,000
Net Cash Flow From Financing Activities -6,000 -7,000 -15,000 9,423,000
Net Cash Flow From Financing Activities, Continuing -6,000 -7,000 -15,000 9,423,000
Net Cash Flow From Investing Activities -70,000 -11,000 -22,000 14,728,000
Net Cash Flow From Investing Activities, Continuing -70,000 -11,000 -22,000 14,728,000
Net Cash Flow From Operating Activities -4,827,000 -3,938,000 -3,257,000 -15,149,000
Net Cash Flow From Operating Activities, Continuing -4,827,000 -3,938,000 -3,257,000 -15,149,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-12 2022-08-11 2022-11-08 2023-03-03
Comprehensive Income/Loss -4,473,000 -4,286,000 -3,868,000 -14,452,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -4,475,000 -4,285,000 -3,868,000 -14,452,000
Other Comprehensive Income/Loss 0 0 -3,868,000 -14,452,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-12 2022-08-11 2022-11-08 2023-03-03
Basic Earnings Per Share 0 0 0 -84
Benefits Costs and Expenses 6,397,000 6,497,000 5,933,000 23,059,000
Cost Of Revenue 824,000 1,150,000 806,000 3,788,000
Costs And Expenses 6,397,000 6,497,000 5,933,000 23,059,000
Diluted Earnings Per Share 0 0 0 -84
Gross Profit 1,102,000 1,063,000 1,259,000 4,755,000
Income/Loss From Continuing Operations After Tax -4,473,000 -4,286,000 -3,870,000 -14,525,000
Income/Loss From Continuing Operations Before Tax -4,471,000 -4,284,000 -3,868,000 -14,516,000
Income Tax Expense/Benefit 2,000 2,000 2,000 9,000
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -4,473,000 -4,286,000 -3,870,000 -14,525,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -4,473,000 -4,286,000 -3,870,000 -14,525,000
Net Income/Loss Available To Common Stockholders, Basic -4,473,000 -4,286,000 -3,870,000 -14,525,000
Operating Expenses 5,518,000 5,364,000 5,179,000 21,926,000
Operating Income/Loss -4,416,000 -4,301,000 -3,920,000 -17,171,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 1,926,000 2,213,000 2,065,000 8,543,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2021-08-12 2021-11-10 2022-03-03
Assets UNPUB 29,640,000 34,095,000 30,417,000
Current Assets UNPUB 28,224,000 32,725,000 28,126,000
Current Liabilities UNPUB 3,603,000 3,795,000 3,307,000
Equity UNPUB 25,996,000 29,981,000 25,947,000
Equity Attributable To Noncontrolling Interest UNPUB 0 0 0
Equity Attributable To Parent UNPUB 25,996,000 29,981,000 25,947,000
Liabilities UNPUB 3,644,000 4,114,000 4,470,000
Liabilities And Equity UNPUB 29,640,000 34,095,000 30,417,000
Noncurrent Assets UNPUB 1,416,000 1,370,000 2,291,000
Noncurrent Liabilities UNPUB 0 319,000 1,163,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2021-08-12 2021-11-10 2022-03-03
Exchange Gains/Losses UNPUB 0 0 -4,000
Net Cash Flow UNPUB -3,915,000 4,453,000 9,768,000
Net Cash Flow, Continuing UNPUB -3,915,000 4,453,000 9,772,000
Net Cash Flow From Financing Activities UNPUB -14,000 8,993,000 27,871,000
Net Cash Flow From Financing Activities, Continuing UNPUB -14,000 8,993,000 27,871,000
Net Cash Flow From Investing Activities UNPUB -81,000 -54,000 -219,000
Net Cash Flow From Investing Activities, Continuing UNPUB -81,000 -54,000 -219,000
Net Cash Flow From Operating Activities UNPUB -3,820,000 -4,486,000 -17,880,000
Net Cash Flow From Operating Activities, Continuing UNPUB -3,820,000 -4,486,000 -17,880,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2021-08-12 2021-11-10 2022-03-03
Comprehensive Income/Loss UNPUB -4,731,000 -5,272,000 -19,582,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB -4,731,000 -5,272,000 -19,582,000
Other Comprehensive Income/Loss UNPUB 0 -5,272,000 -19,582,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2021-08-12 2021-11-10 2022-03-03
Basic Earnings Per Share UNPUB -1 -1 -3
Benefits Costs and Expenses UNPUB 7,236,000 7,123,000 27,490,000
Cost Of Revenue UNPUB 997,000 733,000 3,430,000
Costs And Expenses UNPUB 7,236,000 7,123,000 27,490,000
Diluted Earnings Per Share UNPUB -1 -1 -3
Gross Profit UNPUB 1,511,000 1,120,000 4,491,000
Income/Loss From Continuing Operations After Tax UNPUB -4,731,000 -5,272,000 -19,578,000
Income/Loss From Continuing Operations Before Tax UNPUB -4,728,000 -5,270,000 -19,569,000
Income Tax Expense/Benefit UNPUB 3,000 2,000 9,000
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss UNPUB -4,731,000 -5,272,000 -19,578,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Net Income/Loss Attributable To Parent UNPUB -4,731,000 -5,272,000 -19,578,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB -4,731,000 -5,272,000 -19,653,000
Operating Expenses UNPUB 6,237,000 6,371,000 24,017,000
Operating Income/Loss UNPUB -4,726,000 -5,251,000 -19,526,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB 0 0 75,000
Preferred Stock Dividends And Other Adjustments UNPUB 0 0 75,000
Revenues UNPUB 2,508,000 1,853,000 7,921,000
Calendar
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-17800.000
★
15:30
United States
-60000.000
★
15:30
United States
53700.000
★
15:30
United States
-135800.000
★★
15:30
United States
4400.000
★
15:30
United States
215400.000
★
15:30
United States
-31400.000
★
15:30
United States
62600.000
★
15:30
United States
1300.000
★
15:30
United States
-9700.000
★
15:30
United States
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
News Stream
News Product / Services Announcement
Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida
MINNEAPOLIS, May 14, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the launch of a new pediatric ultrafiltration program utilizing Nuwellis' Aquadex SmartFlow System® at one of the largest health integrated delivery networks (IDN) in Florida. This program marks an expansion by this network to offer ultrafiltration to its pediatric patients, in addition to its current heart failure and critical care patients.
GlobeNewswire Inc. • 5d ago
Stocks Earnings Releases and Operating Results
Nuwellis, Inc. Announces First Quarter 2024 Financial Results
MINNEAPOLIS, May 07, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the first quarter ended March 31, 2024.
GlobeNewswire Inc. • 1w ago
Calendar Calendar of Events
Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) --  Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter of 2024 on Tuesday, May 7, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update.
GlobeNewswire Inc. • 2w ago
Stocks Financing Agreements
Nuwellis Announces Pricing of $2.7 Million Public Offering
MINNEAPOLIS, April 26, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced the pricing of a public offering of 11,250,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 16,875,000 shares of its common stock at a combined public offering price $0.24 per share (or pre-funded warrant in lieu thereof) and associated warrant. Each share of common stock (or prefunded warrant in lieu thereof) is being sold together with one warrant to purchase one and a half shares of common stock. The warrants will have an exercise price of $0.40 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance.
GlobeNewswire Inc. • 3w ago
Health Health
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference
- Analysis demonstrates the statistically superior benefits of ultrafiltration therapy in heart failure events and heart failure hospitalizations compared to intravenous loop diuretics- Artificial intelligence and machine learning-based model show that lifestyle and clinical factors can be strong predictors of heart failure events
GlobeNewswire Inc. • 2mo ago
News Conference Calls/ Webcasts
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
MINNEAPOLIS, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the fourth quarter and full year of 2023 on Tuesday, March 5, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update.
GlobeNewswire Inc. • 2mo ago
Stocks Financing Agreements
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced that, effective February 20, 2024, the Company’s independent directors approved equity awards under Nuwellis’ 2021 Inducement Plan, as material inducements to two individuals entering into employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder-approved equity plan.
GlobeNewswire Inc. • 2mo ago
Health Health
Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference
Nuwellis to share three presentations highlighting the company’s Aquadex SmartFlow system Nuwellis to share three presentations highlighting the company’s Aquadex SmartFlow system
GlobeNewswire Inc. • 2mo ago
News Product / Services Announcement
Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter
Specialty catheter provides alternative peripheral access for ultrafiltration therapy across a greater range of patient physiologies Specialty catheter provides alternative peripheral access for ultrafiltration therapy across a greater range of patient physiologies
GlobeNewswire Inc. • 4mo ago
Stocks Changes in company's own shares
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MINNEAPOLIS, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced that, effective November 14, 2023, the Company’s independent directors approved equity awards under Nuwellis’ 2021 Inducement Plan, as material inducements to five individuals entering into employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder-approved equity plan.
GlobeNewswire Inc. • 6mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT